{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:50:22Z","timestamp":1772495422666,"version":"3.50.1"},"reference-count":73,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>The introduction of direct-acting antiviral agents (DAAs) into clinical practice has revolutionized the therapeutic approach to patients with chronic hepatitis C virus (HCV) infection. According to the most recent guidelines, the first line of treatment for HCV infection involves the use of one of three pan-genotypic DAA combinations, sofosbuvir\/velpatasvir (SOF\/VEL), glecaprevir\/pibrentasvir (GLE\/PIB), and sofosbuvir\/velpatasvir\/voxilaprevir (SOF\/VEL\/VOX). These drugs have been shown to be effective and safe in numerous clinical trials and real-world studies, but special populations have been neglected. Among the special populations to be treated are elderly patients, whose numbers are increasing in clinical practice. The management of these patients can be challenging, in particular due to multiple comorbidities, polypharmacotherapy, and potential drug\u2013drug interactions. This narrative review aims to summarize the current scientific evidence on the efficacy and safety of DAAs in the elderly population, both in clinical trials and in real-life settings. Although there is still a paucity of real-world data and no clinical trials have yet been conducted in the population aged \u2265 75 years old, some considerations about the efficacy and safety of DAAs in the elderly can be made based on the results of these studies. The pan-genotypic associations of DAAs appear to be as efficacious and safe in the elderly population as in the general population; this is both in terms of similar sustained virologic response (SVR) rates and similar frequencies of adverse events (AEs). However, further studies specifically involving this patient population would be necessary to confirm this evidence.<\/jats:p>","DOI":"10.3390\/tropicalmed8110502","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T07:33:18Z","timestamp":1700292798000},"page":"502","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hepatitis C Virus Infection in the Elderly in the Era of Direct-Acting Antivirals: Evidence from Clinical Trials and Real Life"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6466-1412","authenticated-orcid":false,"given":"Nicola","family":"Pugliese","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy"},{"name":"Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Polverini","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy"},{"name":"Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Arcari","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy"},{"name":"Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"De Nicola","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7520-744X","authenticated-orcid":false,"given":"Francesca","family":"Colapietro","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy"},{"name":"Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Masetti","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Ormas","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4838-7366","authenticated-orcid":false,"given":"Roberto","family":"Ceriani","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0561-7902","authenticated-orcid":false,"given":"Ana","family":"Lleo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy"},{"name":"Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy"},{"name":"Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,18]]},"reference":[{"key":"ref_1","unstructured":"(2022). The Polaris Observatory HCV Collaborators Global Change in Hepatitis C Virus Prevalence and Cascade of Care between 2015 and 2020: A Modelling Study. Lancet Gastroenterol. Hepatol., 7, 396\u2013415."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jiph.2019.11.015","article-title":"Overview of Hepatitis C Infection, Molecular Biology, and New Treatment","volume":"13","author":"Rabaan","year":"2020","journal-title":"J. Infect. Public. Health"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mazzaro, C., Quartuccio, L., Adinolfi, L.E., Roccatello, D., Pozzato, G., Nevola, R., Tonizzo, M., Gitto, S., Andreone, P., and Gattei, V. (2021). A Review on Extrahepatic Manifestations of Chronic Hepatitis c Virus Infection and the Impact of Direct-Acting Antiviral Therapy. Viruses, 13.","DOI":"10.3390\/v13112249"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1060028019871352","article-title":"Hepatitis C Treatment Differences in Elderly Patients: Single-Center Retrospective Study","volume":"54","author":"Qureshi","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/MCG.0000000000000872","article-title":"Race, Age, and Geography Impact Hepatitis C Genotype Distribution in the United States","volume":"53","author":"Gordon","year":"2019","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0168-8278(00)00097-0","article-title":"Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c","volume":"34","author":"Poynard","year":"2001","journal-title":"J. Hepatol."},{"key":"ref_7","first-page":"4588","article-title":"Age at Infection Affects the Long-Term Outcome of Transfusion-Associated Chronic Hepatitis C","volume":"99","author":"Minola","year":"2002","journal-title":"Transfus. Med."},{"key":"ref_8","first-page":"9270","article-title":"Epidemiology and Natural History of Hepatitis C Virus Infection","volume":"20","author":"Lee","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1007\/s10620-015-3717-6","article-title":"Hepatitis C Infection in the Elderly","volume":"60","author":"Saab","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/liv.14126","article-title":"Efficacy and Safety of Direct-Acting Antivirals for Hepatitis C in the Elderly: A Systematic Review and Meta-Analysis","volume":"39","author":"Herrmann","year":"2019","journal-title":"Liver Int."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Piecha, F., G\u00e4n\u00dfler, J.M., Ozga, A.K., Wehmeyer, M.H., Dietz, J., Kluwe, J., Laschtowitz, A., von Felden, J., Sterneck, M., and Jordan, S. (2020). Treatment and Re-Treatment Results of HCV Patients in the DAA Era. PLoS ONE.","DOI":"10.1371\/journal.pone.0232773"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL Recommendations on Treatment of Hepatitis C: Final Update of the Series\u2606","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2019.07.020","article-title":"Real-Life Effectiveness and Safety of Sofosbuvir\/Velpatasvir\/Voxilaprevir in Hepatitis C Patients with Previous DAA Failure","volume":"71","author":"Degasperi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mangia, A., Piazzolla, V., Giannelli, A., Visaggi, E., Minerva, N., Palmieri, V., Carraturo, I., Potenza, D., Napoli, N., and Lauletta, G. (2019). SVR12 Rates Higher than 99% after Sofosbuvir\/Velpatasvir Combination in HCV Infected Patients with F0-F1 Fibrosis Stage: A Real World Experience. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215783"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","article-title":"Real-World Effectiveness and Safety of Glecaprevir\/Pibrentasvir in 723 Patients with Chronic Hepatitis C","volume":"70","author":"Pasulo","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mangia, A., Scaglione, F., Toniutto, P., Pirisi, M., Coppola, N., Di Perri, G., Nieto, G.A., Calabrese, S., Hernandez, C., and Perrone, V. (2021). Drug\u2013Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. Int. J. Environ. Res. Public. Health, 18.","DOI":"10.3390\/ijerph18137144"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s12072-022-10402-y","article-title":"Drug\u2013Drug Interactions between Direct-Acting Antivirals and Co-Medications: A Territory-Wide Cohort Study","volume":"16","author":"Hui","year":"2022","journal-title":"Hepatol. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.24926\/iip.v10i3.2144","article-title":"Influential Factors of Successful Hepatitis C Treatment in Elderly Patients","volume":"10","author":"Andres","year":"2019","journal-title":"Innov. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/14740338.2021.1921144","article-title":"Directly Acting Antivirals Are Safe and Effective in HCV Positive Patients Aged 80 Years and Older: A Multicenter Real-Life Study","volume":"20","author":"Pugliese","year":"2021","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/agm2.12190","article-title":"Safety and Efficacy of Directly-Acting Antiviral Therapy for Chronic Hepatitis C Virus in Elderly People","volume":"4","author":"Maggi","year":"2021","journal-title":"Aging Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C Guidance 2018 Update: Aasld-Idsa Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"67","author":"Chung","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jhep.2016.02.042","article-title":"Sofosbuvir\/Velpatasvir Improves Patient-Reported Outcomes in HCV Patients: Results from ASTRAL-1 Placebo-Controlled Trial","volume":"65","author":"Younossi","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/cid\/ciw496","article-title":"Ribavirin-Free Regimen with Sofosbuvir and Velpatasvir Is Associated with High Efficacy and Improvement of Patient-Reported Outcomes in Patients with Genotypes 2 and 3 Chronic Hepatitis C: Results from Astral-2 and -3 Clinical Trials","volume":"63","author":"Younossi","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S2468-1253(21)00398-8","article-title":"Safety and Efficacy of Sofosbuvir-Velpatasvir to Treat Chronic Hepatitis C Virus Infection in Treatment-Naive Patients in Rwanda (SHARED-3): A Single-Arm Trial","volume":"7","author":"Kateera","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12072-019-09927-6","article-title":"Sofosbuvir\u2013Velpatasvir Single-Tablet Regimen Administered for 12 Weeks in a Phase 3 Study with Minimal Monitoring in India","volume":"13","author":"Sood","year":"2019","journal-title":"Hepatol. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection","volume":"376","author":"Gordon","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1053\/j.gastro.2016.05.021","article-title":"Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3\/4A Protease Inhibitor GS-9857 in Treatment-Na\u00efve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections","volume":"151","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S2468-1253(21)00399-X","article-title":"Safety and Efficacy of Sofosbuvir\u2013Velpatasvir\u2013Voxilaprevir for Re-Treatment of Chronic Hepatitis C Virus Infection in Patients with Previous Direct-Acting Antiviral Treatment Failure in Rwanda (SHARED-3): A Single-Arm Trial","volume":"7","author":"Gupta","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(18)30118-3","article-title":"Deferred Treatment with Sofosbuvir\u2013Velpatasvir\u2013Voxilaprevir for Patients with Chronic Hepatitis C Virus Who Were Previously Treated with an NS5A Inhibitor: An Open-Label Substudy of POLARIS-1","volume":"3","author":"Gordon","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir\u2013Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00535-017-1391-5","article-title":"Efficacy and Safety of Glecaprevir\/Pibrentasvir in Japanese Patients with Chronic Genotype 1 Hepatitis C Virus Infection with and without Cirrhosis","volume":"53","author":"Chayama","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.29510","article-title":"Efficacy and Safety of Glecaprevir\/Pibrentasvir in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection","volume":"67","author":"Toyoda","year":"2017","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus Pibrentasvir for Chronic Hepatitis C Virus Genotype 1, 2, 4, 5, or 6 Infection in Adults with Compensated Cirrhosis (EXPEDITION-1): A Single-Arm, Open-Label, Multicentre Phase 3 Trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Poordad, F., Pol, S., Asatryan, A., Buti, M., Shaw, D., Ezode, C.H., Felizarta, F., Reindollar, R.W., Gordon, S.C., and Pianko, S. (2018). Glecaprevir\/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology, 67.","DOI":"10.1002\/hep.29671"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/cid\/ciy220","article-title":"Efficacy and Safety of Glecaprevir\/Pibrentasvir in Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study","volume":"67","author":"Rockstroh","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S2468-1253(20)30086-8","article-title":"Glecaprevir\u2013Pibrentasvir to Treat Chronic Hepatitis C Virus Infection in Asia: Two Multicentre, Phase 3 Studies\u2014A Randomised, Double-Blind Study (VOYAGE-1) and an Open-Label, Single-Arm Study (VOYAGE-2)","volume":"5","author":"Wei","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/Pibrentasvir for 8 Weeks in Treatment-Na\u00efve Patients with Chronic HCV Genotypes 1-6 and Compensated Cirrhosis: The EXPEDITION-8 Trial","volume":"72","author":"Brown","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"13543","DOI":"10.1038\/s41598-021-93095-x","article-title":"Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals against Hepatitis C Virus Infection in Taiwan","volume":"11","author":"Chang","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1002\/jmv.27157","article-title":"Real-World Clinical Outcomes of Sofosbuvir and Velpatasvir Treatment in HCV Genotype 1- and 2-Infected Patients with Decompensated Cirrhosis: A Nationwide Multicenter Study by the Japanese Red Cross Liver Study Group","volume":"93","author":"Tada","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00535-020-01733-4","article-title":"Sofosbuvir plus Velpatasvir Treatment for Hepatitis C Virus in Patients with Decompensated Cirrhosis: A Japanese Real-World Multicenter Study","volume":"56","author":"Tahata","year":"2021","journal-title":"J. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/MEG.0000000000001786","article-title":"Efficacy of Sofosbuvir\/Velpatasvir\/Voxilaprevir in Direct-Acting Antiviral Experienced Patients with Hepatitis C Virus","volume":"33","author":"Da","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"E3288","DOI":"10.1093\/cid\/ciaa1318","article-title":"Efficacy and Safety of Sofosbuvir\/Velpatasvir\/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics","volume":"73","author":"Papaluca","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/jvh.13115","article-title":"Real-World Effectiveness of Sofosbuvir\/Velpatasvir\/Voxilaprevir in 573 Direct-Acting Antiviral Experienced Hepatitis C Patients","volume":"26","author":"Belperio","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1007\/s12325-020-01449-0","article-title":"Real-World Clinical Practice Use of 8-Week Glecaprevir\/Pibrentasvir in Treatment-Na\u00efve Patients with Compensated Cirrhosis","volume":"37","author":"Lampertico","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.dld.2020.08.007","article-title":"Effectiveness and Safety of Glecaprevir\/Pibrentasvir in Chronic Hepatitis C Patients: Results of the Italian Cohort of a Post-Marketing Observational Study","volume":"53","author":"Aghemo","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/liv.14170","article-title":"Real-Life Glecaprevir\/Pibrentasvir in a Large Cohort of Patients with Hepatitis C Virus Infection: The MISTRAL Study","volume":"39","author":"Persico","year":"2019","journal-title":"Liver Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"23473","DOI":"10.1038\/s41598-021-03006-3","article-title":"Nationwide Registry of Glecaprevir plus Pibrentasvir in the Treatment of HCV in Taiwan","volume":"11","author":"Huang","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Komaki, Y., Ozono, Y., Nakamura, K., Iwakiri, H., Hasuike, S., Sueta, M., Miike, T., Yamamoto, S., Uto, H., and Kusumoto, K. (2022). Efficacy and Safety of Glecaprevir and Pibrentasvir in Japanese Patients with Hepatitis C Virus Infection Aged 75 Years or Older. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02284-z"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2185\/jrm.2020-004","article-title":"Efficacy and Safety of Glecaprevir and Pibrentasvir Combination Therapy in Old-Aged Patients with Chronic Hepatitis C Virus Infection","volume":"15","author":"Watanabe","year":"2020","journal-title":"J. Rural. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/ggi.13919","article-title":"Efficacy and Safety of Glecaprevir\/Pibrentasvir in Patients with Hepatitis C Virus Infection Aged \u226575 Years","volume":"20","author":"Kinoshita","year":"2020","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/liv.15599","article-title":"Glecaprevir\/Pibrentasvir Is Safe and Effective in Italian Patients with Chronic Hepatitis C Aged 75\u2009Years or Older: A Multicentre Study","volume":"43","author":"Pugliese","year":"2023","journal-title":"Liver Int."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Foster, G.R., Asselah, T., Kopecky-Bromberg, S., Lei, Y., Asatryan, A., Trinh, R., Zadeikis, N., and Mensa, F.J. (2019). Safety and Efficacy of Glecaprevir\/Pibrentasvir for the Treatment of Chronic Hepatitis C in Patients Aged 65 Years or Older. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0208506"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Flisiak, R., Zar\u0119bska-Michaluk, D., Janczewska, E., \u0141api\u0144ski, T., Rogalska, M., Karpi\u0144ska, E., Miku\u0142a, T., Bolewska, B., Bia\u0142kowska, J., and Flejscher-St\u0119pniewska, K. (2021). Five-Year Follow-up of Cured Hcv Patients under Real-World Interferon-Free Therapy. Cancers, 13.","DOI":"10.3390\/cancers13153694"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.3748\/wjg.v28.i30.4182","article-title":"Hepatocellular Carcinoma, Decompensation, and Mortality Based on Hepatitis C Treatment: A Prospective Cohort Study","volume":"28","author":"Choi","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/jvh.13523","article-title":"Liver and Cardiovascular Mortality after Hepatitis C Virus Eradication by DAA: Data from RESIST-HCV Cohort","volume":"28","author":"Calvaruso","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/apt.13343","article-title":"Improvement of Liver Function Parameters in Advanced HCV-Associated Liver Cirrhosis by IFN-Free Antiviral Therapies","volume":"42","author":"Deterding","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/jvh.13261","article-title":"Long-Term Safety and Efficacy Results in Hepatitis C Virus Genotype 1\u2014Infected Patients Receiving Ombitasvir\/Paritaprevir\/Ritonavir + Dasabuvir \u00b1 Ribavirin in the TOPAZ-I and TOPAZ-II Trials","volume":"27","author":"Poordad","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Chekuri, S., Nickerson, J., Bichoupan, K., Sefcik, R., Doobay, K., Chang, S., DelBello, D., Harty, A., Dieterich, D.T., and Perumalswami, P.V. (2016). Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159413"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/jvh.12706","article-title":"Effect of Viral Suppression on Hepatic Venous Pressure Gradient in Hepatitis C with Cirrhosis and Portal Hypertension","volume":"24","author":"Afdhal","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2021.09.013","article-title":"Incidence of Liver- and Non-Liver-Related Outcomes in Patients with HCV-Cirrhosis after SVR","volume":"76","author":"Degasperi","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Yeh, M.L., Liang, P.C., Tsai, P.C., Wang, S.C., Leong, J., Ogawa, E., Jun, D.W., Tseng, C.H., Landis, C., and Tanaka, Y. (2021). Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after Hcv Svr. Cancers, 13.","DOI":"10.3390\/cancers13143455"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3748\/wjg.v28.i1.96","article-title":"Risk of Hepatocellular Carcinoma after Hepatitis C Virus Cure","volume":"28","author":"Chen","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1002\/hep4.2015","article-title":"Elevated Liver Enzymes Predict Morbidity and Mortality despite Antiviral Cure in Patients with Chronic Hepatitis C: Data from the German Hepatitis C-Registry","volume":"6","author":"Tacke","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jgh3.12805","article-title":"Risk Factors for Liver-Related Mortality of Patients with Hepatitis C Virus after Sustained Virologic Response to Direct-Acting Antiviral Agents","volume":"6","author":"Hattori","year":"2022","journal-title":"JGH Open"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical Outcomes in Patients with Chronic Hepatitis C after Direct-Acting Antiviral Treatment: A Prospective Cohort Study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijid.2019.01.011","article-title":"Visual and Brainstem Auditory Evoked Potentials in HCV-Infected Patients before and after Interferon-Free Therapy\u2014A Pilot Study","volume":"80","author":"Bladowska","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jns.2019.02.002","article-title":"Evaluation of Brain Volume Alterations in HCV-Infected Patients after Interferon-Free Therapy: A Pilot Study","volume":"399","author":"Marciniewicz","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e0157832","DOI":"10.1371\/journal.pone.0157832","article-title":"Treatment of Chronic Hepatitis C in the Aged\u2014Does It Impact Life Expectancy? A Decision Analysis","volume":"11","author":"Maor","year":"2016","journal-title":"PLoS ONE"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/liv.13339","article-title":"Direct-Acting Antivirals Combination for Elderly Patients with Chronic Hepatitis C: A Cost-Effectiveness Analysis","volume":"37","author":"Ciaccio","year":"2017","journal-title":"Liver Int."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/8\/11\/502\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:25:28Z","timestamp":1760131528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/8\/11\/502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,18]]},"references-count":73,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["tropicalmed8110502"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed8110502","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,18]]}}}